Oxford Cannabinoid Technologies Holdings Plc confirmed the appointment of Clarissa Sowemimo-Coker as permanent CEO, effective immediately. Clarissa has been with the Company for over four years and was appointed interim CEO in December 2022. Since then, she has successfully led the Company to its first submission to the UK Medicines and Healthcare Products Regulatory Agency and the Wales Research Ethics Committee 2, whilst continuing to build stronger relationships with external stakeholders.
Oxford Cannabinoid Technologies Holdings Plc London S.E.
Equities
OCTP
GB00BMVMRB86
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.115 GBX | -4.17% | 0.00% | -81.60% |
1st Jan change | Capi. | |
---|---|---|
-81.60% | 3.05M | |
+20.78% | 46.93B | |
+37.38% | 39.08B | |
-8.46% | 38.48B | |
+29.97% | 31.01B | |
-12.26% | 26.14B | |
+11.15% | 25.88B | |
+35.07% | 12.53B | |
-6.32% | 11.36B | |
-12.31% | 10.65B |